cempra.comHome - Melinta Therapeutics

CONTAGIOUS IDeas Contact Primary Menu Skip to content Company Our Mission Guiding Principles Management Team Products News Recent Developments Press Releases Join Our Team Contact -- On April 20, 2020, Melinta Therapeutics announced that it successfully completed its financial restructuring and has emerged from Chapter 11. In accordance with the pre-negotiated Chapter 11 plan of reorganization, Melinta is now privately owned by affiliates of Deerfield Management Company, L.P., a healthcare investment firm, resulting in a debt-free, well-financed, and strongly positioned anti-infectives company with plans for future growth. Now more than ever, Melinta remains committed to ensuring that patients have access to critical anti-infectives to treat serious infections, including those caused by drug-resistant bacteria. Melinta will continue to supply, distribute, and support its four marketed antibiotics. And as always, our products will remain fully stocked and available. For additional information regarding Melinta’s successful financial restructuring and partnership with Deerfield, please click here . -- As you may be aware, on December 27, 2019, Melinta announced that the Company had initiated voluntary proceedings under Chapter 11 of the U.S. Bankruptcy Code. We also announced that we reached an agreement with our senior lender that would allow Melinta to emerge from Chapter 11 on an expedited basis under new ownership and continue operating on sound financial footing. Our lender’s proposal to acquire the Company, however, remains subject to a Court-supervised competitive bidding process that could result in higher and better offers. Melinta and its advisors will evaluate any competing bids submitted to ensure the Company receives the highest and best offer for its business in connection with the Chapter 11 process. The closing of any transaction will be subject to Bankruptcy Court approval and the Company aims to complete this process by the end of the first quarter of 2020. Most importantly- we want you to know that Melinta is not closing its doors. Melinta continues to operate with no anticipated disruption to supply, distribution, promotion, or support for any of our antibiotics. Our products also remain fully stocked and available. Melinta's restructuring under Chapter 11 is purely a financial one and we are confident that this process will secure new ownership of the business and the financial resources to support our portfolio and ensure our products continue to be available. -- OK -- -- Trigger the fancybox -- to cure serious infections -- MELINTA THERAPEUTICS, INC. - THE ANTIBIOTICS COMPANY ©2020 ALL RIGHTS RESERVED | Privacy Policy | Terms of Use Menu Company Our Mission Guiding Principles Management Team Products News Recent Developments Press Releases Join Our Team Contact...